Featured Research

from universities, journals, and other organizations

Phase 2 study of MLN8237: Investigational aurora A kinase (aak) inhibitor in patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS)

Date:
December 7, 2010
Source:
John Theurer Cancer Center
Summary:
Aurora A kinase is essential for cell division (mitotic progression) and is amplified or overexpressed in AML and other blood cancers. An investigational drug, MLN8237 is an orally available, potent, and selective AAK inhibitor. It has shown preclinical activity against leukemia, lymphoma, and myeloma, and clinical activity against treatment-resistant cancers in early-stage human trials.

Dr. Stuart Goldberg, Chief, Leukemia, John Theurer Cancer Center led this open-label, multicenter, phase 2 trial of MLN8237 in patients with advanced AML or intermediate/high-risk MDS. AAK is essential for cell division (mitotic progression) and is amplified or overexpressed in AML and other blood cancers. An investigational drug, MLN8237 is an orally available, potent, and selective AAK inhibitor. It has shown preclinical activity against leukemia, lymphoma, and myeloma, and clinical activity against treatment-resistant cancers in early-stage human trials.

Fifty-seven patients with a median age of 72 years old (range 46-85) were enrolled in the current study. Patients received 21-day cycles of MLN8237 (50 mg) for seven days followed by 14 days rest until disease progression or unacceptable toxicity. Forty-six (81%) patients had AML, of whom 21 (37%) had secondary leukemia, while 11 (19%) patients had MDS.

Dr. Goldberg and colleagues concluded MLN8237 has anti-leukemia activity with a 13% response rate (all AML) with advanced, mainly pre-treated disease.

"We found that patients for with rapidly progressive disease, improved outcomes require strategies to enhance both disease control and risk management in early cycles, allowing time needed to achieve clinical benefit from AAK inhibition," said Dr. Goldberg. "Our results support further clinical studies of MLN8237 in heme-lymphatic malignancies and solid tumors."

The Eastern Cooperative Oncology Group, one of the largest clinical cancer research organizations in the United States, previously reported superior one and two-year survival for newly diagnosed symptomatic multiple myeloma patients initially treated with lenalidomide plus low-dose dexamethasone, versus those treated with lenalidomide plus high-dose dexamethasone. As a result of this analysis, lenalidomide plus low-dose dexamethasone is now considered the standard of care.

In this multicenter trial, lead author David Vesole, MD, PhD, FACP, Co- Chief and Director of Research, Multiple Myeloma, John Theurer Cancer Center and colleagues evaluated the impact of age on dexamethasone dose intensity and overall survival.

The study randomly assigned 445 to patients to LD (233 patients) or Ld (222 patients) treatment groups and analyzed data for all enrolled patients ("intent-to-treat" analysis) for overall survival. Patients in the high-dose group did not have better overall survival at any age, while the higher dose was more toxic.

"Our findings confirmed that as originally reported, low-dose dexamethasone should be the standard of care for all newly diagnosed multiple myeloma patients regardless of age," said Dr. Vesole.

This research was presented at the annual meeting of the American Society of Hematology (ASH) taking place December 4-7, 2010 in Orlando, Florida.


Story Source:

The above story is based on materials provided by John Theurer Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

John Theurer Cancer Center. "Phase 2 study of MLN8237: Investigational aurora A kinase (aak) inhibitor in patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS)." ScienceDaily. ScienceDaily, 7 December 2010. <www.sciencedaily.com/releases/2010/12/101207130341.htm>.
John Theurer Cancer Center. (2010, December 7). Phase 2 study of MLN8237: Investigational aurora A kinase (aak) inhibitor in patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS). ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/12/101207130341.htm
John Theurer Cancer Center. "Phase 2 study of MLN8237: Investigational aurora A kinase (aak) inhibitor in patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS)." ScienceDaily. www.sciencedaily.com/releases/2010/12/101207130341.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins